Erratum: AAPM recommendations on dose prescription and reporting methods for permanent interstitial brachytherapy for prostate cancer: Report of Task Group 137: AAPM TG-137 Report (Medical Physics, (2009), 36, 11, (5310-5322), 10.1118/1.3246613);AAPM recommendations on dose prescription and reporting methods for permanent interstitial brachytherapy for prostate cancer: Report of Task Group 137

Medical Physics

Volumn 36, Issue 11, 2009, Pages 5310-5322

  Nath, Ravinder ^a   Bice, William S ^b   Butler, Wayne M ^c   Chen, Zhe ^a   Meigooni, Ali S ^d   Narayana, Vrinda ^e   Rivard, Mark J ^f   Yu, Yan ^g  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b International Medical Physics   (United States)

^c WHEELING HOSPITAL   (United States)

^d NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^e Providence Cancer Center   (United States)

^f TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

Brachytherapy; Prescription; Prostate; Reporting

Indexed keywords

COMPUTERIZED TOMOGRAPHY; DOSIMETRY; IMPLANTS (SURGICAL); MEDICAL PHYSICS; ONCOLOGY; PROBABILITY DISTRIBUTIONS; RADIOISOTOPES; RADIOTHERAPY; TUMORS; ULTRASONICS; UROLOGY;

BRACHYTHERAPY; INTERSTITIAL BRACHYTHERAPY; LOW DOSE RATE IRRADIATION; PRESCRIPTION; PROSTATE; RADIOACTIVE SOURCES; RADIOBIOLOGICAL MODELING; REPORTING;

DISEASES;

CESIUM 131; IODINE 125; PALLADIUM 103; RADIOISOTOPE; UNCLASSIFIED DRUG;

BRACHYTHERAPY; CANCER RISK; COMPUTER ASSISTED TOMOGRAPHY; DOSIMETRY; ECHOGRAPHY; HUMAN; LOW ENERGY RADIATION; NUCLEAR MAGNETIC RESONANCE; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; REVIEW; TREATMENT PLANNING; TUMOR VOLUME;

EID: 70350712610     PISSN: 00942405     EISSN: None     Source Type: Journal    
DOI: 10.1002/mp.13530     Document Type: Erratum

References (73)

1. B. R. Thomadsen, K. Ayyanger, L. Anderson, G. Luxton, W. Hanson, and J. F. Wilson, in Principles and Practice of Brachytherapy, edited by, S. Nag, (Futura, Armonk, NY, 1997).
2. W. L. Smith, " Prostate volume contouring: A 3D analysis of segmentation using 3DTRUS, CT, and MR.," Int. J. Radiat. Oncol., Biol., Phys. 0360-3016 67, 1238-1247 (2007). 10.1016/j.ijrobp.2006.11.027
3. C. Kirisits, " Accuracy of volume and DVH parameters determined with different brachytherapy treatment planning systems.," Radiother. Oncol. 0167-8140 84, 290-297 (2007). 10.1016/j.radonc.2007.06.010 (Pubitemid 47362397)
4. F. A. Siebert, " Phantom investigations on CT seed imaging for interstitial brachytherapy.," Radiother. Oncol. 0167-8140 85, 316-323 (2007). 10.1016/j.radonc.2007.04.036 (Pubitemid 350161002)
5. F. A. Siebert, P. Kohr, and G. Kovacs, " The design and testing of a solid phantom for the verification of a commercial 3D seed reconstruction algorithm.," Radiother. Oncol. 0167-8140 74, 169-175 (2005). 10.1016/j.radonc.2004.10.016 (Pubitemid 40331874)
6. K. R. Badiozamani, " Anticipating prostatic volume changes due to prostate brachytherapy.," Radiat. Oncol. Invest. 1065-7541 7, 360-364 (1999). 10.1002/(SICI)1520-6823(1999)7:6<360::AID-ROI6>3.0.CO;2-D
7. D. Taussky, " Sequential evaluation of prostate edema after permanent seed prostate brachytherapy using CT-MRI fusion.," Int. J. Radiat. Oncol., Biol., Phys. 0360-3016 62, 974-980 (2005). 10.1016/j.ijrobp. 2004.12.012
8. F. M. Waterman, " Edema associated with I-125 or Pd-103 prostate brachytherapy and its impact on post-implant dosimetry: An analysis based on serial CT acquisition.," Int. J. Radiat. Oncol., Biol., Phys. 0360-3016 41, 1069-1077 (1998). 10.1016/S0360-3016(98)00152-7 (Pubitemid 28377488)
9. Y. Yamada, " Impact of intraoperative edema during transperineal permanent prostate brachytherapy on computer-optimized and preimplant planning techniques.," Am. J. Clin. Oncol. 0277-3732 26, 130-135 (2003). 10.1097/01.coc.0000091353.67232.e5
10. F. M. Waterman and A. P. Dicker, " Impact of postimplant edema on V(100) and D(90) in prostate brachytherapy: Can implant quality be predicted on day 0?," Int. J. Radiat. Oncol., Biol., Phys. 0360-3016 53, 610-621 (2002). 10.1016/S0360-3016(02)02751-7 (Pubitemid 34626500)
11. L. Potters, " A comprehensive and novel predictive modeling technique using detailed pathology factors in men with localized prostate carcinoma.," Cancer 0008-543X 95, 1451-1456 (2002). 10.1002/cncr.10869
12. N. Yue, " Optimum timing for image-based dose evaluation of 125I and 103PD prostate seed implants.," Int. J. Radiat. Oncol., Biol., Phys. 0360-3016 45, 1063-1072 (1999). 10.1016/S0360-3016(99)00282-5 (Pubitemid 29525473)
13. Z. Chen, " Dosimetric effects of edema in permanent prostate seed implants: A rigorous solution.," Int. J. Radiat. Oncol., Biol., Phys. 0360-3016 47, 1405-1419 (2000). 10.1016/S0360-3016(00)00549-6 (Pubitemid 30421195)
14. N. N. Stone, " Comparison of intraoperative dosimetric implant representation with postimplant dosimetry in patients receiving prostate brachytherapy.," Brachytherapy 1538-4721 2, 17-25 (2003). 10.1016/S1538-4721(03)00005-9 (Pubitemid 37329402)
15. Z. Chen, " Potential impact of prostate edema on the dosimetry of permanent seed implants using the new C 131 s (model CS-1) seeds.," Med. Phys. 0094-2405 33, 968-975 (2006). 10.1118/1.2179170
16. R. G. Stock, " A dose-response study for I-125 prostate implants.," Int. J. Radiat. Oncol., Biol., Phys. 0360-3016 41, 101-108 (1998). 10.1016/S0360-3016(98)00006-6 (Pubitemid 28211308)
17. J. E. Sylvester, " The Seattle Prostate Institute approach to treatment planning for permanent implants.," in Basic and Advanced Techniques in Prostate Brachytherapy, edited by, A. P. Dicker, G. S. Merrick, F. M. Waterman, R. K. Valicenti, and, L. G. Gomella, (Taylor & Francis, London, 2005).
18. K. Wallner, J. Roy, and L. Harrison, " Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy.," Int. J. Radiat. Oncol., Biol., Phys. 0360-3016 32, 465-471 (1995). 10.1016/0360-3016(94)00599-G
19. C. Salembier, " Tumour and target volumes in permanent prostate brachytherapy: A supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy.," Radiother. Oncol. 0167-8140 83, 3-10 (2007). 10.1016/j.radonc.2007.01.014 (Pubitemid 46527942)
20. J. F. Williamson, " Guidance to users of Nycomed Amersham and North American Scientific, Inc., I-125 interstitial sources: Dosimetry and calibration changes: Recommendations of the American Association of Physicists in Medicine Radiation Therapy Committee Ad Hoc Subcommittee on low-energy seed dosimetry.," Med. Phys. 0094-2405 26, 570-573 (1999). 10.1118/1.598570 (Pubitemid 29186277)
21. J. F. Williamson, " Recommendations of the American Association of Physicists in Medicine on P 103 d interstitial source calibration and dosimetry: Implications for dose specification and prescription.," Med. Phys. 0094-2405 27, 634-642 (2000). 10.1118/1.598923 (Pubitemid 30227038)
22. B. R. Prestidge, " Cesium-131 permanent prostate brachytherapy: An initial report.," Int. J. Radiat. Oncol., Biol., Phys. 0360-3016 63, S336-S337 (2005).
23. N. Yue, " Prescription dose in permanent (131)Cs seed prostate implants [Erratum appears in Med. Phys. 33(7), 2655 (2006)].," Med. Phys. 0094-2405 32, 2496-2502 (2005). 10.1118/1.1951062 (Pubitemid 41197186)
24. J. Musmacher, R. Byrnes, K. Satchwill, and L. Rumpf, " Dosimetric computaion of cesium-131 and palladium-103 for permanent prostate brachytherapy.," Med. Phys. 0094-2405 34, 2440 (2007). 10.1118/1.2760830
25. 131Cs: a consensus report from the Cesium Advisory Group.," Brachytherapy 1538-4721 7, 290-296 (2008). 10.1016/j.brachy.2008.05.004
26. 125I prostate implants using interventional magnetic resonance imaging.," Int. J. Radiat. Oncol., Biol., Phys. 0360-3016 46, 207-214 (2000). 10.1016/S0360-3016(99)00422-8 (Pubitemid 30021501)
27. R. A. Cormack, C. M. Tempany, and A. V. D'Amico, " Optimizing target coverage by dosimetric feedback during prostate brachytherapy.," Int. J. Radiat. Oncol., Biol., Phys. 0360-3016 48, 1245-1249 (2000). 10.1016/S0360-3016(00)00742-2 (Pubitemid 30802163)
28. J. F. Carrier, " Postimplant dosimetry using a Monte Carlo dose calculation engine: A new clinical standard.," Int. J. Radiat. Oncol., Biol., Phys. 0360-3016 68, 1190-1198 (2007). 10.1016/j.ijrobp.2007.02.036
29. G. K. Edmundson, D. Yan, and A. A. Martinez, " Intraoperative optimization of needle placement and dwell times for conformal prostate brachytherapy.," Int. J. Radiat. Oncol., Biol., Phys. 0360-3016 33, 1257-1263 (1995). 10.1016/0360-3016(95)00276-6
30. J. Stromberg, " Ultrasound-guided high dose rate conformal brachytherapy boost in prostate cancer: Treatment description and preliminary results of a phase I/II clinical trial.," Int. J. Radiat. Oncol., Biol., Phys. 0360-3016 33, 161-171 (1995). 10.1016/0360-3016(95)00035-W
31. Y. Yu, T. Podder, Y. Zhang, W. S. Ng, V. Misic, J. Sherman, L. Fu, D. Fuller, E. Messing, D. Rubens, J. Strang, and R. Brasacchio, " Robot-assisted prostate brachytherapy.," in Medical Image Computing and Computer-Assisted Intervention-MICCAI 2006, edited by, R. Larsen, M. Nielsen, and, J. Sporring, (Springer, Heidelberg, 2006), Vol. 4190, pp. 41-49, Paper No. LNCS41900041.
32. Z. Wei, " Robot-assisted 3D-TRUS guided prostate brachytherapy: System integration and validation.," Med. Phys. 0094-2405 31, 539-548 (2004). 10.1118/1.1645680 (Pubitemid 38381016)
33. G. Fichtinger, " Robotically assisted prostate brachytherapy with transrectal ultrasound guidance-Phantom experiments.," Brachytherapy 1538-4721 5, 14-26 (2006). 10.1016/j.brachy.2005.10.003
34. V. Misic, L. Fu, T. K. Podder, L. Liao, D. J. Rubens, R. Brasacchio, E. M. Messing, J. G. Strang, W. S. Ng, and Y. Yu, " Dynamic planning in single needle brachytherapy systems.," Int. J. CARS 1, 271-273 (2006). 1861-6410
35. W. S. Bice, Jr., B. R. Prestidge, and M. F. Sarosdy, " Sector analysis of prostate implants.," Med. Phys. 0094-2405 28, 2561-2567 (2001). 10.1118/1.1418016 (Pubitemid 34031544)
36. G. S. Merrick, " Prostate cancer distribution in patients diagnosed by transperineal template-guided saturation biopsy.," Eur. Urol. 0302-2838 52, 715-723 (2007). 10.1016/j.eururo.2007.02.041 (Pubitemid 47126150)
37. A. S. Barnes, " Magnetic resonance spectroscopy-guided transperineal prostate biopsy and brachytherapy for recurrent prostate cancer.," Urology 0090-4295 66, 1319 (2005).
38. R. J. Ellis and D. A. Kaminsky, " Fused radioimmunoscintigraphy for treatment planning.," Rev. Urol. 8, S11-S19 (2006). 1523-6161
39. J. F. Fowler, " The linear-quadratic formula and progress in fractionated radiotherapy.," Br. J. Radiol. 0007-1285 62, 679-694 (1989). 10.1259/0007-1285-62-740-679
40. R. G. Dale and B. Jones, " The clinical radiobiology of brachytherapy.," Br. J. Radiol. 0007-1285 71, 465-483 (1998).
41. R. G. Dale, " The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy.," Br. J. Radiol. 0007-1285 58, 515-528 (1985). 10.1259/0007-1285-58-690-515
42. 125I seeds.," Int. J. Radiat. Oncol., Biol., Phys. 0360-3016 28, 971-978 (1994).
43. C. C. Ling, " Permanent implants using Au-198, Pd-103 and I-125: Radiobiological considerations based on the linear quadratic model.," Int. J. Radiat. Oncol., Biol., Phys. 0360-3016 23, 81-87 (1992).
44. G. R. Lazarescu and J. J. Battista, " Analysis of the radiobiology of ytterbium-169 and iodine-125 permanent brachytherapy implants.," Phys. Med. Biol. 0031-9155 42, 1727-1736 (1997). 10.1088/0031-9155/42/9/005 (Pubitemid 27400358)
45. 125I based on radiobiological effectiveness and dosimetry.," Semin Urol. Oncol. 1081-0943 18, 152-159 (2000).
46. C. I. Armpilia, " The determination of radiobiologically optimized half-lives for radionuclides used in permanent brachytherapy implants.," Int. J. Radiat. Oncol., Biol., Phys. 0360-3016 55, 378-385 (2003). 10.1016/S0360-3016(02)04208-6 (Pubitemid 36069096)
47. A. B. Jani, " Biological effective dose for comparison and combination of external beam and low-dose rate interstitial brachytherapy prostate cancer treatment plans.," Med. Dosim. 0739-0211 29, 42-48 (2004). 10.1016/j.meddos.2003.09.005 (Pubitemid 38352831)
48. R. G. Stock, " Biologically effective dose values for prostate brachytherapy: Effects on PSA failure and posttreatment biopsy results.," Int. J. Radiat. Oncol., Biol., Phys. 0360-3016 64, 527-533 (2006). 10.1016/j.ijrobp.2005.07.981
49. A. Niemierko, " Reporting and analyzing dose distributions: A concept of equivalent uniform dose.," Med. Phys. 0094-2405 24, 103-110 (1997). 10.1118/1.598063 (Pubitemid 27051935)
50. X. A. Li, " Dose escalation in permanent brachytherapy for prostate cancer: Dosimetric and biological considerations.," Phys. Med. Biol. 0031-9155 48, 2753-2765 (2003). 10.1088/0031-9155/48/17/302 (Pubitemid 37121458)
51. A. Haworth, " Assessment of I-125 prostate implants by tumor bioeffect.," Int. J. Radiat. Oncol., Biol., Phys. 0360-3016 59, 1405-1413 (2004). 10.1016/j.ijrobp.2004.01.047
52. M. Zaider, " Treatment planning for prostate implants using magnetic-resonance spectroscopy imaging.," Int. J. Radiat. Oncol., Biol., Phys. 0360-3016 47, 1085-1096 (2000). 10.1016/S0360-3016(00)00557-5 (Pubitemid 30345610)
53. S. L. Tucker, H. D. Thames, and J. M. Taylor, " How well is the probability of tumor cure after fractionated irradiation described by Poisson statistics? [see comment].," Radiat. Res. 0033-7587 124, 273-282 (1990). 10.2307/3577839
54. M. Zaider and G. N. Minerbo, " Tumour control probability: A formulation applicable to any temporal protocol of dose delivery.," Phys. Med. Biol. 0031-9155 45, 279-293 (2000). 10.1088/0031-9155/45/2/303 (Pubitemid 30096764)
55. M. Zaider and L. Hanin, " Biologically-equivalent dose and long-term survival time in radiation treatments.," Phys. Med. Biol. 0031-9155 52, 6355-6362 (2007). 10.1088/0031-9155/52/20/017 (Pubitemid 350093198)
56. J. Z. Wang, M. Guerrero, and X. A. Li, " How low is the alpha/beta ratio for prostate cancer? [see comment].," Int. J. Radiat. Oncol., Biol., Phys. 0360-3016 55, 194-203 (2003). 10.1016/S0360-3016(02)03828-2 (Pubitemid 36020360)
57. J. Z. Wang, " The low alpha/beta ratio for prostate cancer: What does the clinical outcome of HDR brachytherapy tell us?," Int. J. Radiat. Oncol., Biol., Phys. 0360-3016 57, 1101-1108 (2003). 10.1016/S0360-3016(03) 00747-8 (Pubitemid 37324129)
58. J. Z. Wang, " Effect of edema, relative biological effectiveness, and dose heterogeneity on prostate brachytherapy.," Med. Phys. 0094-2405 33, 1025-1032 (2006). 10.1118/1.2181294
59. J. F. Fowler, " What hypofractionated protocols should be tested for prostate cancer?," Int. J. Radiat. Oncol., Biol., Phys. 0360-3016 56, 1093-1104 (2003). 10.1016/S0360-3016(03)00132-9 (Pubitemid 36794043)
60. O. Chibani and J. F. Williamson, " MCPI: A sub-minute Monte Carlo dose calculation engine for prostate implants.," Med. Phys. 0094-2405 32, 3688-3698 (2005). 10.1118/1.2126822
61. A. S. Meigooni and R. Nath, " Tissue inhomogeneity correction for brachytherapy sources in a heterogeneous phantom with cylindrical symmetry.," Med. Phys. 0094-2405 19, 401-407 (1992). 10.1118/1.596894
62. J. J. DeMarco, " CT-based dosimetry calculations for I 125 prostate implants.," Int. J. Radiat. Oncol., Biol., Phys. 0360-3016 45, 1347-1353 (1999). 10.1016/S0360-3016(99)00343-0
63. 125I brachytherapy implants.," Med. Phys. 0094-2405 19, 385-390 (1992). 10.1118/1.596871
64. G. S. Burns and D. E. Raeside, " The accuracy of single-seed dose superposition for I-125 implants.," Med. Phys. 0094-2405 16, 627-631 (1989). 10.1118/1.596320 (Pubitemid 19224314)
65. J. F. Carrier, " Impact of interseed attenuation and tissue composition for permanent prostate implants.," Med. Phys. 0094-2405 33, 595-604 (2006). 10.1118/1.2168295 (Pubitemid 43320163)
66. H. Afsharpour, " A Monte Carlo study on the effect of seed design on the interseed attenuation in permanent prostate implants.," Med. Phys. 0094-2405 35, 3671-3681 (2008). 10.1118/1.2955754
67. H. D. Thames, " An incomplete-repair' model for survival after fractionated and continuous irradiations.," Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med. 0020-7616 47, 319-339 (1985). 10.1080/09553008514550461
68. R. G. Dale, " Calculation of integrated biological response in brachytherapy.," Int. J. Radiat. Oncol., Biol., Phys. 0360-3016 38, 633-642 (1997). 10.1016/S0360-3016(97)00096-5 (Pubitemid 27305026)
69. S. P. Lee, " Biologically effective dose distribution based on the linear quadratic model and its clinical relevance.," Int. J. Radiat. Oncol., Biol., Phys. 0360-3016 33, 375-389 (1995). 10.1016/0360-3016(95)00162-R
70. Z. Chen and R. Nath, " Biologically effective dose (BED) for interstitial seed implants containing a mixture of radionuclides with different half-lives.," Int. J. Radiat. Oncol., Biol., Phys. 0360-3016 55, 825-834 (2003). 10.1016/S0360-3016(02)04282-7 (Pubitemid 36170022)
71. T. E. Wheldon, " The linear-quadratic transformation of dose-volume histograms in fractionated radiotherapy.," Radiother. Oncol. 0167-8140 46, 285-295 (1998). 10.1016/S0167-8140(97)00162-X (Pubitemid 28157279)
72. L. B. Marks, " Incorporation of functional status into dose-volume analysis.," Med. Phys. 0094-2405 26, 196-199 (1999). 10.1118/1.598503 (Pubitemid 29094245)
73. Y. Lu, D. R. Spelbring, and G. T. Chen, " Functional dose-volume histograms for functionally heterogeneous normal organs.," Phys. Med. Biol. 0031-9155 42, 345-356 (1997). 10.1088/0031-9155/42/2/007 (Pubitemid 27095071)